Bladder cancer occurs when the cells inside your bladder grow abnormally and form a tumor. It can happen at any age, but the most common affected group is older adults. Besides, males are more likely to get bladder cancer than females.
On May 18th, 2016, the U.S. Food and Drug Administration approved a new drug to treat locally advanced or metastatic urothelial carcinoma. Urothelial carcinoma is the most common type of bladder cancer. The new drug is called tecentriq(atezolizumab) and it is a type of immunotherapy treatment.
Cancer cells can preferentially make off-switches to evade the immune system and then spread throughout the body. Tecentriq(atezolizumab) can help control the off-switches so that the immune system can fight the cancer cells.
According to the FDA, the new drug has some side effects, including decreased appetite, nausea, fatigue, a fever, urinary tract infections and constipation.
Keywords: bladder cancer new treatments; new bladder cancer treatment; new treatment bladder cancer